Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Automated Manufacturing Poised to Revolutionize CAR T Cell Therapy Production

The cell and gene therapy (CGT) field is on the brink of a major transformation as next-generation automation technologies promise to bridge the gap between groundbreaking science and real-world patient demand. Recent developments in automated manufacturing systems are set to address longstanding challenges in CAR T cell therapy production, potentially leading to faster development, improved global consistency, and broader patient access.

NoahAI News1/6/2026

Biotech IPO Market Slows in 2025 as Investors Grow More Selective

The biopharmaceutical industry experienced a significant slowdown in initial public offerings (IPOs) during 2025, with only eight companies completing public market debuts compared to 19 in 2024. This marked decrease reflects a more discerning investment landscape, as the sector continues to adjust following years of market correction post-pandemic.

NoahAI News1/6/2026

FDA Clears First In-Ear EEG Device, Revolutionizing Brain Monitoring

Naox Technologies has achieved a significant milestone in the field of brain monitoring with the FDA clearance of its innovative in-ear electroencephalography (EEG) device, Naox Link. This groundbreaking technology promises to transform the way brain activity is monitored, offering new possibilities for neurology, epilepsy care, sleep studies, and clinical research.

NoahAI News1/6/2026

Eli Lilly's Ambitious Revenue Target Hinges on Oral Obesity Drug Market

Eli Lilly is poised for significant growth, with projections indicating a potential revenue surge to $94.3 billion by 2027. This ambitious target, representing a 109% increase from 2024's $45 billion, is largely contingent on the company's performance in the burgeoning oral obesity drug market.

NoahAI News1/6/2026

Novo Nordisk Launches Oral Wegovy in US, Intensifying Competition in Obesity Market

Novo Nordisk has officially launched its highly anticipated oral version of Wegovy in the United States, marking a significant milestone in the pharmaceutical industry's efforts to combat obesity. The introduction of this groundbreaking pill-form treatment comes amidst intensifying competition in the weight loss medication market, with rival Eli Lilly hot on Novo's heels.

NoahAI News1/6/2026

J&J Halts Phase IIb Eczema Trial as $1.25B Asset Falls Short on Efficacy

Johnson & Johnson has announced the early termination of its Phase IIb DUPLEX-AD trial for JNJ-95475939 (JNJ-5939), a bispecific antibody targeting IL-4 and IL-31 for the treatment of moderate-to-severe atopic dermatitis. The decision came after an interim analysis revealed the asset failed to meet the company's high efficacy standards, marking a significant setback for the pharmaceutical giant's atopic dermatitis pipeline.

NoahAI News1/6/2026

AbbVie Enters $1 Billion Deal for Trispecific Lung Cancer Drug, Challenging Amgen's Imdelltra

AbbVie has made a significant move in the competitive lung cancer drug market, securing rights to a promising trispecific T-cell engager in a deal potentially worth over $1 billion. The agreement positions AbbVie to challenge Amgen's recently approved Imdelltra, intensifying the race to develop effective treatments targeting the DLL3 protein in small cell lung cancer (SCLC).

NoahAI News1/6/2026

Bausch + Lomb Renews Commitment to Glaucoma Awareness and Research

Bausch + Lomb, a leading eye health company, has launched its annual glaucoma awareness and fundraising initiatives for 2026, continuing its long-standing commitment to combating the progressive eye disease. The company's efforts include partnerships with prominent organizations in the field and support for innovative research and treatment options.

NoahAI News1/6/2026

Moderna Seeks Approval for mRNA Flu Vaccine, Eyes Future Growth

Moderna, the biotechnology company known for its mRNA-based COVID-19 vaccine, has taken a significant step forward in its efforts to diversify its product portfolio and secure future revenue streams. The company has filed approval applications for a new seasonal flu vaccine, marking a crucial milestone in its strategy to leverage its mRNA technology platform beyond the pandemic.

NoahAI News1/6/2026

Zenas BioPharma's Obexelimab Falls Short in IgG4-Related Disease Trial, Shares Plummet

Zenas BioPharma's experimental drug obexelimab has met the primary endpoint in a Phase 3 trial for IgG4-related disease, but the results have failed to impress investors and analysts, leading to a significant drop in the company's stock price. The trial outcomes, while positive, appear to fall short when compared to a recently approved competitor, raising questions about the drug's commercial viability.

NoahAI News1/6/2026

Daiichi Sankyo Unveils $1.9 Billion Global Manufacturing Expansion for Enhertu

Daiichi Sankyo has announced plans to invest approximately 300 billion yen ($1.9 billion) in expanding its manufacturing capabilities for the antibody-drug conjugate (ADC) Enhertu across multiple countries. The move comes as the company aims to solidify its position in the ADC market and mitigate potential geopolitical risks.

NoahAI News1/6/2026

MetaVia's Dual Agonist Shows Promise in Obesity Treatment, Joining Competitive Field

MetaVia, a biotechnology company formerly known as NeuroBo Pharmaceuticals, has reported encouraging results from a phase 1 trial of its dual agonist DA-1726, designed to target both GLP-1 and glucagon receptors for obesity treatment. The study, which involved adults with obesity who were otherwise healthy, demonstrated an average weight loss of 9.1% after eight weeks of treatment with a 48-mg non-titrated dose.

NoahAI News1/6/2026

«1...6 7 8...67 »